PSA (contexto de detección y vigilancia del cáncer de próstata — grado C de USPSTF)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BIO-PSA-PROSTATE-SCREENING |
|---|---|
| Tipo | Biomarcador |
| Aliaces | Criterios de detección de PSAAntigénio específico de la próstata para la detecciónPSA séricoПСА (скринінг/нагляд раку передміхурової залози — USPSTF C) |
| Situación | reviewed 2026-05-18 | pending_clinical_signoff |
| Enfermedades | DIS-PROSTATE |
| Fuentes | SRC-NCCN-PROSTATE-2025 SRC-USPSTF-PROSTATE-2018 |
Datos sobre biomarcadores
| Tipo de biomarcador | serum_marker |
|---|---|
| Medición | MétodoSerum immunoassay (ECLIA, CLIA); WHO 96/670 calibration preferred Unidadesng/mL Alcance típico
|
| Productos químicos y químicos | BIO-PSA |
Notas
Screening-context entry for PSA — separate from BIO-PSA (which covers diagnostic and treatment-monitoring dynamics for established prostate cancer). USPSTF 2018: Grade C for men 55-69 (individualized shared-decision-making about benefits + harms); Grade D for men ≥70 (recommend AGAINST routine screening). NCCN 2025 (Early Detection): baseline PSA + DRE discussion at age 45 for African American men or BRCA2 carriers (high-risk groups), age 50 for average risk; if PSA <1 ng/mL, repeat every 2-4 years; if PSA 1-3 ng/mL, repeat every 1-2 years; if PSA >3 ng/mL, evaluate further (repeat PSA, mpMRI, biomarker reflex such as 4Kscore/PHI, possible biopsy). Higher screening intensity for confirmed BRCA2 germline carriers (IMPACT study — PSA q1y starting age 40; biopsy threshold ≥3 ng/mL). PSA can be falsely elevated in BPH, prostatitis, urinary retention, recent instrumentation. Free PSA ratio, PSA density, and reflex biomarkers (PHI, 4Kscore, SelectMDx) reduce unnecessary biopsy. Limitations: overdiagnosis/overtreatment of indolent cancers (well-characterized harm — driver of USPSTF Grade C). STUB pending two-Co-Lead signoff.
Utilizado por
Relevancia terapéutica
BMA-PSA-PROSTATE-USPSTF-SHARED-DECISION- La detección del PSA para el cáncer de próstata lleva una recomendación de grado C del USPSTF para hombres de 55 años...